Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-16T06:03:44.247Z Has data issue: false hasContentIssue false
  • English
  • Français

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation

Published online by Cambridge University Press:  13 August 2021

A. Galanopoulos ,
E. Tsiolka ,
P. Ntounas ,
D. Mpelimpasakis ,
D. Karakoutas ,
N. Sidiropoulos ,
I. Mpougiouklis ,
K. Kyziridis  and
E. Papalexi
A. Galanopoulos*
Affiliation:
Medical, Lundbeck Hellas, Athens, Greece
E. Tsiolka
Affiliation:
Psychiatric, Private Office, Athens, Greece
P. Ntounas
Affiliation:
Psychiatric, Private Office, Athens, Greece
D. Mpelimpasakis
Affiliation:
Psychiatric, Private Office, Athens, Greece
D. Karakoutas
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
N. Sidiropoulos
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
I. Mpougiouklis
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
K. Kyziridis
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
E. Papalexi
Affiliation:
Medical, Lundbeck Hellas, ATHENS, Greece
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015).

Objectives

The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece.

Methods

In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses.

Results

336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons).

Conclusions

MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales.

Conflict of interest

A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas.

Keywords

MoodFunctionalityPatient-ratedVortioxetine
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S334
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.